Off-the-Shelf CAR-T therapy takes on relapsed blood cancers
NCT ID NCT06662227
First seen Jan 23, 2026 · Last updated May 24, 2026 · Updated 24 times
Summary
This early-phase study tests a "universal" CAR-T cell therapy (UWD-CD19) for people with B-cell lymphoma or leukemia that has not responded to standard treatments. About 30 participants will receive a single infusion of these engineered immune cells after a short chemotherapy course. The main goals are to check safety and see if the treatment can shrink tumors, with follow-up lasting at least five years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, 710061, China
Conditions
Explore the condition pages connected to this study.